Lv1
10 积分 2025-02-27 加入
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
2个月前
已完结
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
2个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2个月前
已完结
Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications
3个月前
已完结
Non‐Invasive Tumor Budding Evaluation and Correlation with Treatment Response in Bladder Cancer: A Multi‐Center Cohort Study
3个月前
已关闭
Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges
4个月前
已完结
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis
4个月前
已完结
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis
4个月前
已关闭
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
4个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
4个月前
已关闭
皖公网安备34019202002308
